GSK Reports Cancer Study Data, Including 62% Response Rate
Updated Phase I ovarian cancer results for Mo—Rez showed a 62% confirmed response rate at the selected Phase III dose, with median duration of response of 12.2 months after more than 13 months of follow-up. The supplied report also references rectal cancer studies but provides no results for them.